Cardiol Therapeutics Inc.
NASDAQ:CRDL
1.38 (USD) • At close August 1, 2025
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Omzet
| 0 | 0 | 0 | 0.079 | 0 | 0 | 0 | 0 |
| Kosten van de omzet
| 0 | 0.248 | 0.22 | 0 | 0.23 | 0.151 | 0.091 | 0.053 |
| Brutowinst
| 0 | -0.248 | -0.22 | 0.079 | -0.23 | -0.151 | -0.091 | -0.053 |
| Brutowinstmarge
| 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Onderzoek- en ontwikkelingskosten
| 14.012 | 14.224 | 18.962 | 10.87 | 10.515 | 3.53 | 1.533 | 0.441 |
| Algemene en administratieve kosten
| 26.265 | 15.561 | 22.374 | 27.873 | 9.946 | 10.447 | 5.87 | 1.101 |
| Verkoop- en marketingkosten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Verkoop-, algemene en administratieve kosten
| 26.265 | 15.561 | 22.374 | 27.873 | 9.946 | 10.447 | 5.87 | 1.101 |
| Overige kosten
| 0 | 0 | 0.164 | 0.112 | 0.007 | 0.299 | 0 | -0.061 |
| Bedrijfskosten
| 40.277 | 29.786 | 41.336 | 38.744 | 20.69 | 14.128 | 7.494 | 1.595 |
| Bedrijfsresultaat
| -40.277 | -29.786 | -50.339 | -45.473 | -20.606 | -13.584 | -7.39 | -1.589 |
| Bedrijfsresultaat ratio
| 0 | 0 | 0 | -577.363 | 0 | 0 | 0 | 0 |
| Totaal overige inkomsten en kosten netto
| 3.599 | 1.657 | 10.405 | 7.027 | -0.034 | -1.941 | -8.503 | -0.072 |
| Inkomen voor belasting
| -36.677 | -28.128 | -30.931 | -31.638 | -20.641 | -13.684 | -15.894 | -1.661 |
| Inkomen voor belasting ratio
| 0 | 0 | 0 | -401.704 | 0 | 0 | 0 | 0 |
| Belastingkosten
| 0 | 0 | -10.241 | -6.914 | 0.007 | 0.299 | 0.663 | 0.061 |
| Nettowinst
| -36.677 | -28.128 | -30.931 | -31.638 | -20.641 | -13.684 | -15.894 | -1.661 |
| Nettowinstmarge
| 0 | 0 | 0 | -401.704 | 0 | 0 | 0 | 0 |
| WPA (Winst Per Aandeel)
| -0.51 | -0.44 | -0.49 | -0.73 | -0.69 | -0.53 | -0.66 | -0.073 |
| Verwaterde WPA
| -0.51 | -0.44 | -0.49 | -0.73 | -0.69 | -0.53 | -0.66 | -0.073 |
| EBITDA
| -40.115 | -29.59 | -41.156 | -38.444 | -20.461 | -11.767 | -7.299 | -1.504 |
| EBITDA ratio
| 0 | 0 | 0 | -488.121 | 0 | 0 | 0 | 0 |